Skip to content
Search

Latest Stories

Pakistan's Wasim Khan urges England to 'do the right thing' in 2022

Pakistan's decision to tour England despite the risks of travelling during the COVID-19 pandemic was not part of a reciprocal agreement but the Pakistan Cricket Board (PCB) expects its English counterpart to "do the right thing" in 2022.

Pakistan are the second test team, after West Indies, to tour England this summer. They will play three tests, the first beginning on Wednesday, and three Twenty20 Internationals in bio-secure venues in Manchester and Southampton.


England last visited Pakistan in 2005 and are slated to return in 2022, but the top teams have so far declined to tour since a 2009 attack on Sri Lanka's team bus in Lahore.

PCB chief executive Wasim Khan said on Thursday that the tour of England would stand them in good stead.

"Will that benefit Pakistan cricket in future? Of course it will," he told a PCB podcast.

"Have we struck a deal with them right now for them to come? ... Of course we didn't. Now is not the time to do that. It's all about timing.

"Conversations will take place with ECB (England and Wales Cricket Board) and they will do the right thing by us as well."

After years of staging 'home' tests in neutral venues due to security concerns, Pakistan played their first test on home soil since 2009 against Sri Lanka in December last year and have hosted Bangladesh this year.

Khan said the PCB had put the game's interests ahead of its own.

"We are making decisions not just for what's good for Pakistan, but what's right for global cricket.

"Showing solidarity is absolutely the right thing for us to be doing. West Indies are doing it, we've done it."

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less